Market Cap (In TWD)
2.66 Billion
Revenue (In TWD)
5.08 Million
Net Income (In TWD)
-212.29 Million
Avg. Volume
104.51 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 23.2-44.0
- PE
- -13.1
- EPS
- -1.84
- Beta Value
- 0.641
- ISIN
- TW0006580004
- CUSIP
- -
- CIK
- -
- Shares
- 110590000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Chien Du-Shieng Ph.D.
- Employee Count
- -
- Website
- https://www.trx.com.tw
- Ipo Date
- 2017-06-21
- Details
- TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in patient's blood Se level and immune system; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.
More Stocks
-
PCKPainChek Limited
PCK
-
7750Syntec
7750
-
603708Jiajiayue Group Co., Ltd.
603708
-
JQ79North Inc.
JQ
-
8917
-
601187Xiamen Bank Co., Ltd.
601187
-
9580
-
5113